Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 17, 2024 04:00 ET | Source: AKAMPION

ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base

Existing investors and new investor Double Point Ventures join forces to support ImmunOs TherapeuticsInvestment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers ...
December 11, 2023 04:00 ET | Source: AKAMPION

ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023

HLA/SIRPa bispecifics targeting LILRB1/2 plus CD47 checkpoint receptorDesigned to target myeloid, NK and T cells and to be precisely directed to tumor sitesPotent in vitro anti-tumor efficacy...
May 24, 2023 04:00 ET | Source: AKAMPION

ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002

- First-in-class checkpoint inhibitor IOS-1002 (targeting LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1) being evaluated as mono and combination therapy in patients with advanced solid tumors Schlieren...
April 25, 2023 04:00 ET | Source: AKAMPION

ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board

- Renowned immunology expert from MD Anderson Cancer Center to lead seasoned group of scientific advisors Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – April 25, 2023 –...